BLUEライブシグナル | Getagraph.comで利益を最大化

売る 108132 min ago

@ $1.019

発行日: 14 2月 2024 @ 23:30

リターン: -4.91%

前回のシグナル: 2月 13 - 02:12

前回のシグナル: 買う

リターン: -3.90 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:42):

Stats
本日の出来高	3.37M
平均出来高	8.33M
時価総額	186.71M
EPS	$0 ( 2024-04-03 )
次の収益日	( $-0.470 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.540
ATR14	$0.00300 (0.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Colvin Richard A	Buy	199 000	Stock Option (right to buy)
2024-03-01	Colvin Richard A	Sell	6 770	Common Stock
2024-03-01	Vittiglio Joseph	Buy	199 000	Stock Option (right to buy)
2024-03-01	Obenshain Andrew	Buy	650 000	Stock Option (right to buy)
2024-03-04	Obenshain Andrew	Sell	6 095	Common Stock

INSIDER POWER
92.23
Last 95 transactions
Buy: 3 237 593 \| Sell: 214 711

ボリューム相関

長: 0.29 (neutral)

短: 0.02 (neutral)

Signal:(50.958) Neutral

bluebird bio Inc 相関

10 最も正の相関
ALXO	0.973
YJ	0.949
ORPH	0.947
CSSEP	0.946
PMVP	0.946
KNSA	0.945
GOOD	0.944
NAKD	0.944
IPA	0.943
EVLO	0.943

10 最も負の相関
CPAQ	-0.961
MCAA	-0.958
SCOB	-0.957
LGACU	-0.957
ABGI	-0.957
FICV	-0.957
AGGR	-0.957
LGAC	-0.957
LVRA	-0.955
KAII	-0.955

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

bluebird bio Inc 相関 - 通貨/商品

0.00
( neutral )

-0.07
( neutral )

bluebird bio Inc 財務諸表

Annual	2022
収益:	$3.60M
総利益:	$-6.48M (-180.15 %)
EPS:	$-3.39

FY	2022
収益:	$3.60M
総利益:	$-6.48M (-180.15 %)
EPS:	$-3.39

FY	2021
収益:	$3.66M
総利益:	$-35.20M (-961.09 %)
EPS:	$-11.89

FY	2020
収益:	$250.73M
総利益:	$245.34M (97.85 %)
EPS:	$-9.95

Financial Reports:

No articles found.

bluebird bio Inc

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.